|
NSAIDS CONCURRENT ADMINISTRATION SHOULD BE CAUTIOUS AS THESE INHIBIT PROSTAGLANDIN SECRETIONS WHICH MAY REDUCE THE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ACETAMINOPHEN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
CO-ADMINISTRATION MAY INTERFERE WITH THE BENEFITS OF ASPIRIN TAKEN FOR HEART DISEASE, SHOULD BE TAKEN ON DIFFERENT TIMES
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS INHIBIT SPREADING ACTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY CAUSE CARBACHOL INEFFECTIVE
|
CO-ADMINISTRATION CAN BE ASSOCIATED WITH INCREASED OCCULT GASTROINTESTINAL BLOOD LOSS ; AT HIGH CONCENTRATION IN VITRO, CLOPIDOGREL INHIBITS P450IIC9, IT MAY INTERFERE WITH THE METABOLISM OF MANY NON-STEROIDAL ANTI-INFLAMMATORY AGENTS
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
ANTICOAGULANT EFFECT IS INCREASED
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|